Pubmed    Pubmed Central		uBio Home | uBioRSS
WebSearch Literature Molecular Images

uBio  Web  Results 1 - 10 of about 4497 Synonyms:    Dota  Broader Terms:    Unassigned      External Resources: Did you mean: Dooth, Dot, Dotha, Doththa, Dotia, Dott or Dottia? 1.  Engineering of 177Lu-labeled gold encapsulated into dendrimeric nanomaterials for the treatment of lung cancer. Wang Z, Ye M, Ma D, Shen J, Fang F Journal of biomaterials science. Polymer edition, 2021 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=0 2.  Diagnostic value of 68 Ga-DOTATATE PET-CT imaging for staging of ER+ /PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18 F-FDG PET-CT in a prospective pilot trial. Nguyen A, Fullard K, Sheehan-Dare G, Tang R, Chan L, Ho B, Dear R, Keane J, Hickey A, Nandurkar R, Chen J, Chen A, Lim E, Emmett L Journal of medical imaging and radiation oncologyJ Med Imaging Radiat OncolDiagnostic value of 68 Ga-DOTATATE PET-CT imaging for staging of ER+ /PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18 F-FDG PET-CT in a prospective pilot trial.10.1111/1754-9485.1334218 F-Fludeoxyglucose PET-CT (FDG) is increasingly used to stage breast cancer. Most breast cancers express the Oestrogen Receptor (ER) and Progesterone Receptor (PR), and this subtype demonstrates lower activity on FDG imaging. Somatostatin receptors (SSTR) offer a potentially improved radiotracer target for ER+ /PR+ breast cancer. We present the first in?vivo clinical study comparing 68 Ga-DOTATATE PET-CT (DOTA) to FDG and conventional imaging (bone scan and diagnostic CT), in metastatic ER+ /PR+ human epidermal growth factor receptor 2 (HER2) negative breast cancer.Patients with clinically progressive metastatic ER+ /PR+ HER2- breast cancer underwent restaging with DOTA, FDG and conventional imaging. Scans were analysed visually, and semi-quantitatively. Wilcoxon-Rank Scoring was used to assess significance.Ten women (mean age 57?years) underwent imaging. 8/10 demonstrated disease on both DOTA and FDG. 2/10 positive on conventional imaging, but DOTA- /FDG- , and had no disease progression at 1-year follow-up. Heterogeneity of uptake was seen between DOTA and FDG with 5 bone lesions DOTA+ /FDG- and 1 bone lesion FDG+ /DOTA- . Twenty-one visceral lesions were FDG+ /DOTA- (2 patients), with 10/21 identified on conventional imaging. Maximum standard uptake values (SUV max) of DOTA were greater than FDG (10.9 vs. 6.6, P?=?ns). Four sites were biopsied (3 patients). 3/4 had high ER/PR expression (mean DOTA SUV max 9.4) and 1/4 low ER/PR expression (DOTA SUV max 3.1).Whilst we have not demonstrated DOTA to be superior to FDG in staging of ER+ /PR+ breast cancers, DOTA may have a role in assessing HR status and treatment decisions; further evaluation of this is warranted.© 2021 The Royal Australian and New Zealand College of Radiologists.NguyenAndrewADepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.FullardKarenKDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.Sheehan-DareGemmaGhttps://orcid.org/0000-0003-2092-7922Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.TangReubenRDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.ChanLynLDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.HoBaoBDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.DearRachelRGarvan Institute of Medical Research, Sydney, New South Wales, Australia.KeaneJoanneJDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.HickeyAdamADepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.NandurkarRohanRDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.ChenJuliaJSt Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.Garvan Institute of Medical Research, Sydney, New South Wales, Australia.ChenAndrewADepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.LimElgeneESt Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.Garvan Institute of Medical Research, Sydney, New South Wales, Australia.EmmettLouiseLDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia.St Vincent's Clinical School, UNSW, Sydney, New South Wales, Australia.Garvan Institute of Medical Research, Sydney, New South Wales, Australia.eng$25,000St. Vincent's Clinic FoundationJournal Article20211021AustraliaJ Med Imaging Radiat Oncol1014693401754-9477IM68Ga-DOTATATEPET-CTmetastatic breast cancer20201230202108222021102271320211023602021102360aheadofprint3467667510.1111/1754-9485.13342